Stocktoria
Teva Pharmaceutical Industries Limited TEVA.TA
IL · Tel Aviv Stock Exchange · XTAE · stock · Healthcare · website
Teva Pharmaceutical Industries Limited financials (annual, from 10-K)
Bars are annual figures from 2022 to 2025; red bars are negative (a loss or cash outflow).
| Metric | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|
| Revenue | $17.3B | $16.5B | $15.8B | $14.9B |
| Gross profit | $8.9B | $8.1B | $7.6B | $7.0B |
| R&D expense | $1.0B | $998.0M | $953.0M | $838.0M |
| SG&A expense | $4.0B | $3.7B | $3.5B | $3.4B |
| Operating income | $4.0B | $3.4B | $3.2B | $2.7B |
| Interest expense | $916.0M | $1.0B | $1.0B | $930.0M |
| Income tax | -$180.0M | $676.0M | -$7.0M | -$643.0M |
| Net income | $1.4B | -$1.6B | -$559.0M | -$2.4B |
| EPS (diluted) | $1.21 | $-1.45 | $-0.50 | $-2.12 |
| Operating cash flow | $1.6B | $1.2B | $1.4B | $1.6B |
| Free cash flow | $1.1B | $749.0M | $842.0M | $1.0B |
| Cash & equivalents | $3.6B | $3.3B | $3.2B | $2.8B |
| Inventory | $3.2B | $3.0B | $4.0B | $3.8B |
| Total assets | $40.7B | $39.3B | $43.5B | $44.0B |
| Total liabilities | $32.8B | $33.6B | $35.4B | $35.4B |
| Shareholders' equity | $7.9B | $5.4B | $7.5B | $7.8B |
Growth · year-over-year · Revenue CAGR 5%
| Metric | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|
| Revenue growth | +4.3% | +4.4% | +6.2% | — |
| Free cash flow growth | +53.3% | -11.0% | -19.2% | — |
Each column is the change versus the prior fiscal year. Growth off a negative or zero base is shown as “—”. CAGR is the compound annual revenue growth across the years shown.
Source: company filings via Yahoo Finance · IL · as of 2025-12-31. Figures in USD; non-US fundamentals are aggregated by Yahoo (shorter history); facts plus Stocktoria's own computed scores — not investment advice.